Angle Share Discussion Threads

[givmesunshine] 18/10/2022 14:20

Hi Yel

That was a rant / moan - I get your point though .. im holding a big loss, I do agree on the comments on the investors etc and the last 2 RNS are hardly inspiring - however today RNS sends the bb nutters into a frenzy, while the contentt makes perfect sence.. When all are losing thier minds its may well be time to buy.. im not leveaged and not buying any more, but thing a a ltte crazy at the moment and other than noise the company is in a better position that it way in June (but the share price isnt) Big concern is 5 months - is that really a big concern ? when its falling we all look down and vise vera - blaming AN is just an excuse

GLA - Ive heard from my broker mate that we will get an RNS Tommorow..something about reducing AGL stationary spend to get 1 day cash runway (insider knowledge dont trade it)

[purchaseatthetop] 18/10/2022 14:18

All good points and respectfully put yelrom. Thanks. I just disagree with your interpretation that AN does no5 care about investors, cancer sufferers and so on. He said a couple of careless things that haveeen overblown.

I am waiting for lab certification and the first proper new contract. Which will arrive. Until then I will add like I did from 40p ages ago. Except now we have FDA, ovarian and 24 months cash.

[nigelc43] 18/10/2022 14:17

Yelrom, You should email that to Newland

[waterloo01] 18/10/2022 14:13

All fair points and well made. I've been of the view for sometime, that for the sake of the product and getting it into use, never mind shareholder value, it really needs one of the bigger players to integrate and advance Parsortix. I assumed, and still hope that would happen post FDA.

[yelrom] 18/10/2022 14:03

First up thanks to those posting with reasoned and balanced views on what is increasingly becoming just another example of a company with all the characteristics of a two bit AIM share. Albeit we actually do have a functioning product we also have poor and self interested leadership, poor communication with shareholders, inadequate governance and commitment from free loading NED's and now the final requirement, a previously reasonable bulletin board that had stood the test of time for over 10 years descending into a bickering farce.

Just a few weeks ago I said I would hold out of FOMO. Have to the say with every bit of communication from Newland and Angle since FDA approval my FOMO rating has significantly moderated. I was never one to get carried away with the outrageous valuations posted by others or indeed any Newland suggested himself, in fact in many ways I see that as a red flag. However I did think with FDA approval and correct marketing it was not unreasonable to think we could ultimately be holders in a £500 million company. Frankly now I'm looking at this and wondering if we do have a way to market at all.

The latest RNS asserts we have enough runway until H2 2024. So to me this immediately implies little or no revenue from the already FDA approved product for two years at least. So the plan is to obtain more research results for other cancers and FDA approvals whilst we have no commercialisation for two years of the already granted one. Is this what talks with numerous parties results in. Newland could be talking to 20 or 200 companies, it's academic if that's all it is, talk.
And as for announcing a distributor. Surely with such a product finding distributors is a formality albeit maybe premature given the lack of revenue forecasts.

And even if these talks are substantive his loose mouth has already shown his hand. He has already stated his lack of concern for shareholders of the 'wrong type' and then allowed his ego and hubris to state 'I don't need the money'. As a negotiator I am then wondering what he does want. It follows, he doesn't care about shareholders and he doesn't need money so all that's left is his ego and image. So why even pay a market price never mind a premium when all Newland wants are plaudits. Previous posters have pointed to the fact that Abbott and the like have billions of dollars to spare so paying a good price for this technology will mean little to them. Unfortunately their motivation is much like Newland's in that whilst they do not need the money either their ego's are satisfied by doing the deal for as little as possible. Newland has shown his hand and is out of his depth. Abbott and the like couldn't care less whether this product gets to cancer sufferers now or ever. What they get off on is the same as countless other American companies and that is the kudos of picking up someone else's idea for as little as possible and commercialising it.

As I said before putting aside the current financial failure and despite my loyalty as a LTH my other major regret is that this product is not helping people now. We've all been touched by friends or family receiving cancer treatment, sometimes unnecessary and invasive that this product can mitigate, so it's an absolute indictment of Newland and the finance and pharma industries that this product is being brought to market so slowly and indeed if at all.

Rather than letting the company go to what looks like now an inevitable cheap distressed buyout in a couple of years to either Americans or private equity it would be better to gift the technology to our own NHS. Although I fully accept the caveat that it is an organisation hardly blessed with any ability to successfully administrate such a gift given like the rest of our public sector it is staffed by so called graduates from the Blair vision of education. I can fully imagine the head of procurement with their History of Art degree trying to implement the roll out of Parsortix to the needy. Maybe not.

Newland really has underperformed thus far for us. Let's face it he is talking to a market and industry that fell for the Elizabeth Holmes illusion. What was it 7 billion dollar valuation of a con trick. And yet we've got the FDA approval that she never had or would of. Perhaps in his next negotiation he should don a blonde wig, dispense with his glasses, put in some blue contacts, bright red lipstick, adopt a intense stare and throw in a sob story about a sick relative.

Joking aside, the guy has shown immense dedication to get this FDA approval but in light of this performance since then we are well overdue some communication from him clarifying his comment about shareholders types and his own personal objectives together with a clear strategy of how we are going to achieve some shareholder value and when we are going to see cancer patients benefitting from this product.
Until then I am still of the opinion that it all points to a wasted investment for the sake of one man's ego and his perceived legacy. It all points to the outcome of forced sale to private equity and Newland and his cabal picking up their inevitable sweetners. It's then we see he probably does care about money, just not anyone else's.

Finally just for context and irony. I am literally resigned to losing money after holding for over 12 years on a ground breaking product which mitigates invasive treatment of cancer sufferers. I even imagined there might be one day when I or a friend or loved one would find help from Parsortix and I could feel some satisfaction in my support of it. And yet by comparison a brief investment on a certain little pink cartoon pig brought me one of my best multi bag returns in years of investing.

Sorry for what has turned into a bit of a rant and I sincerely hope Mr Newland proves me wrong.

[antonagis] 18/10/2022 13:49

PURCHASE suggests recovery in another desperate attempt to rally the troops. With AN running the business side that just won’t happen IMO. As much chance of a recovery as the other stocks ramped up by the likes of PURCHASE, namely Bushveld, ENET and ITX to name just a few.

[antonagis] 18/10/2022 13:46

49p.. This is finished. AMARETTO and PURCHASE have done their best to prop it up with their incessant ramping but with muppets running the business side this was always going to fail as I’ve stated for a long while. This will now NEVER RECOVER. The only hope is a buy out at well below the average of most.

[spaceparallax] 18/10/2022 13:06

I'm happy to stick with AN - he has more skin in the game than any potential successor. Parsortix is too big a medical gamechanger for AGL to fail in its commercialisation. The recent share price decline is more a function of malign nature of today's predatory markets that seek to make money from manipulation of sp; what a sad world we live in.

[purchaseatthetop] 18/10/2022 12:52

Why on earth should AN resign or do anything except deliver the business? He has done nothing wrong and the share price is where it is because holders are selling. I will happily buy them and they will recover.

[gibso6767] 18/10/2022 12:45

if AN resigned or other from AGL unless the bottom was reached I personally think it would be a bad move and his networking ,experience would be sorely missed at every level

[halland75] 18/10/2022 12:44

47p sell.
Convict has a 77p avg.

All Amarepoo's buys yesterday, like him are all LOSERS 🤣

What Prawns.
Love it 😀

[halland75] 18/10/2022 12:42

I see that 50p sell was being optimistic lol.
Down to a 47p sell.
Convict has a 77p avg and his twin dope AmarePoo numerous buys yesterday are all losses. What Losers! 😊

Bahahaha!

[moonshine3] 18/10/2022 12:08

Three bidders RNS for shanti gold

18 October 2022

Shanta Gold Limited

("Shanta" or the "Company")

Statement regarding possible offer

The Board of Shanta Gold Limited ("Shanta") notes a recent press article and confirms that it has received approaches from Shandong Gold Group Co., Ltd ("Shandong"), Yintai Gold Co., Ltd ("Yintai") and Chaarat Gold Holdings Ltd ("Chaarat") which may or may not result in an offer for the Company.

Whilst discussions are continuing with each party, there can be no certainty that an offer will be made, nor as to the terms on which any offer might be made. Further announcements will be made in due course, as appropriate. In the meantime, Shanta shareholders are advised to take no action.

applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code. This announcement has not been made with the consent of Shandong, Yintai or Chaarat.

[zeus19] 18/10/2022 11:51

Im not too worried about the current share price Its falling on minor volumes. They have a cash runway far into 24 so unless your portfolio relies on Angle commercializing Parsortix in the next few months, I wouldnt be too worried. People expected overnight commercial deals following FDA clearance but give me an example of when thats happened with other pharmas. Its unheard of. Talks take time, especially ironing out the finer detail and when theres 20 different discussions taking place. FDA clearance was received at the end of May. Its been less than 5 months since so wouldnt surprise me at all if we had a sudden influx of news by the end of the FY.If you have a look at the overall market, many profitable companies are near their all time or 24 month lows. Its not just Angle

[parob] 18/10/2022 11:45

Just waiting for the big sell print to show then this will really move.

[amaretto1] 18/10/2022 11:44

He used to be ....AGL have moved on ....U say nose dive of share price ????Have u seen share price today ???

[amaretto1] 18/10/2022 11:43

The Science sells this company ... not Andrew Newland ..Who just over seen a complete destruction of wealth ....Are Abbot going hostile ??? Or Beckman Coulter

[zeus19] 18/10/2022 11:42

Probably nose drive. He has a great relationship with many investors and pharmas. I think hes key to Angles future success

[amaretto1] 18/10/2022 11:41

Plenty people work for AGL who are capable......Go to website ....Look at the board

[marketshaker] 18/10/2022 11:39

Simple question to all.

What would happen to share price if AN resigned/sacked?

[chesty1] 18/10/2022 11:35

daicaprice18 Oct '22 - 11:28 - 14888 of 14889
0 3 0
Caught the dip ,far too oversold now.

Good luck with that, chart says no but fingers crossed it is for you longs.

[bermudashorts] 18/10/2022 11:29

74tom,

The post you have copied across from lse shows a lack of understanding of the changes to the R&D legislation and the complexity of the issue.

Proposed changes to overseas R&D tax credits were announced a good while ago but HMRC only published draft guidance in late July. The UK Bioindustry Association, and I'm sure other industry bodies have been in negotiations with HMRC and have submitted a formal response to the draft guidance and held further meetings to discuss proposed changes. A good example is the running of clinical trials where recruitment of patients drives the need for overseas trials.

So in short, there will be exemptions and under certain circumstances companies will still be able to claim overseas R&D tax credits, but the rules are yet to be finalised. Against that backdrop, the prudent course of action for any CEO would be to evaluate the likely impact of the changes as we get closer to the final outcome and put in place an appropriate strategy - and that's exactly what Angle have done.

Incidently, if you're invested in any other bios, it might be worth checking to see whether they carry out overseas R&D, including clinical trials. This is not an issue that's unique to Angle.